Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Experiencing Unusual Activity Mid-day

Marco Green
May 26, 2017

It maintains its BUY rating on Aerie shares and raises its 12-month price target to $60 based on a modest de-risking of Roclatan in the firm's DCF model. The stock increased 0.46% or $0.51 during the last trading session, reaching $110.85.

About 15,893 shares traded. About shares traded. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since May 24, 2016 and is uptrending.

"Roclatan is distinguished by its ability to lower intraocular pressure to levels previously unseen with current glaucoma therapies, including market-leading latanoprost", said Aerie's Chief Medical Officer, Richard A. Lewis. Cowen and Company reissued an "outperform" rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, April 18th. Neuberger Berman Limited Company owns 1.60M shares. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It now has negative earnings.

The 90-day trial compared Roclatan - a combination of Rhopressa (netarsudil ophthalmic solution 0.02%) and latanoprost - with monotherapy of each of its components.

Since February 14, 2017, it had 1 buying transaction, and 1 sale for $1.90 million activity.

Shares outstanding are recorded as 34.21 M and total shares floated are 33.02 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 15.50. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Therefore 100% are positive.

Roclatan's results, along with a nearing regulatory decision for Rhopressa, mark Aerie's progress in moving closer to market - achievements that could make it an attractive acquisition target, Steadman suggested.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, May 2nd. The lowest target is $50.0 while the high is $69.0. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has "Buy" rating given on Thursday, October 6 by Stifel Nicolaus. On Wednesday, September 9 the stock rating was initiated by JMP Securities with "Market Outperform". The firm has "Buy" rating by Canaccord Genuity given on Tuesday, December 20. The rating was reinitiated by Cantor Fitzgerald with "Buy" on Friday, June 3. Stifel Nicolaus maintained the stock with "Buy" rating in Thursday, October 6 report.

Disciplined Growth Investors Inc decreased Autodesk Inc Com (ADSK) stake by 0.63% reported in 2016Q4 SEC filing. Its down 1.36, from 2.49 in 2016Q3.

A number of hedge funds and other institutional investors have recently made changes to their positions in AERI.

Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on August, 2. Manchester Cap Mgmt Limited Liability Com reported 150 shares. Iguana Health Lc invested in 115,000 shares. Boulegeris holds 1.86% or 80,935 shares in its portfolio. Jpmorgan Chase And invested 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Venbio Select Advisor Llc owns 610,000 shares or 4.66% of their USA portfolio.

HP reported adjusted earnings of 40 cents per share on revenue of $12.39 billion for the fiscal second quarter, better than analysts were expecting. First Mercantile Tru Communication accumulated 5,411 shares. Finally, BlackRock Fund Advisors boosted its position in Aerie Pharmaceuticals by 7.3% in the third quarter. Analysts forecast EPS of $-0.74, up exactly $0.13 or 14.94 % from 2014's $-0.87 EPS.

Investors sentiment decreased to 1.54 in Q4 2016. 2,973 shares were sold by BECKER JAN, worth $229,159. Stifel Finance holds 0.02% or 93,551 shares. 50,000 are held by Acuta Capital Prtnrs Limited Co. Confluence Invest Mngmt Ltd Co has invested 0.06% in BIO-TECHNE Corp (NASDAQ:TECH). Weiss Multi reported 66,000 shares. The company was maintained on Wednesday, November 4 by RBC Capital Markets. Weatherbie has 117,434 shares. Falcon Point Cap Lc owns 0.1% invested in Xencor Inc (NASDAQ:XNCR) for 28,043 shares. Essex Inv Management Ltd Liability reported 0.73% stake. (NASDAQ:ADSK) or 52,419 shares. Moreover, Baldwin Brothers Inc Ma has 0.07% invested in the company for 13,750 shares. $10,357 worth of BIO-TECHNE Corp (NASDAQ:TECH) shares were sold by LUCAS ROGER C. MCDOWELL MARY T had sold 20,000 shares worth $1.76M on Thursday, March 16. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article